title: [New medications for patients with type 2 diabetes].
abstract: Type 2 diabetes is characterised by insulin resistance and deficiencywhich explains the multitude of molecules developed for its treatment.The beneficial effects of metformin and sulfamides have been demonstrated. Over the last 10 years, new molecules have appeared: acarbose, repaglinide and incretins.
authors.forename: Lucie
authors.initials: L
authors.lastname: Meillet
mesh_terms: D002219:Carbamates / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D052216:Glucagon-Like Peptide 1 / Q000819:agonists; D065089:Glycoside Hydrolase Inhibitors / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D054795:Incretins / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use
chemical_list: D002219:Carbamates; D054873:Dipeptidyl-Peptidase IV Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins; D010880:Piperidines; C072379:repaglinide; D052216:Glucagon-Like Peptide 1